Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukemia in children.

C H Pui1

  • 1Department of Hematology/Oncology and Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.

Current Opinion in Oncology
|February 25, 2000
PubMed
Summary

Risk-directed therapy for acute lymphoblastic leukemia (ALL) requires more than genetics. Measuring minimal residual disease and considering genetic polymorphisms improves treatment accuracy and minimizes toxicity for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood.

Leukemia & lymphoma·2016
Same author

A revised definition for cure of childhood acute lymphoblastic leukemia.

Leukemia·2014
Same author

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Cancer chemotherapy and pharmacology·2014
Same author

Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

Pediatric blood & cancer·2014
Same author

Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.

Journal of the National Cancer Institute·2012

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Genetics

Background:

  • Long-term event-free survival in childhood acute lymphoblastic leukemia (ALL) approaches 80%.
  • Current risk assignment systems based solely on primary genetic abnormalities are insufficient for personalized treatment.
  • Leukemias with specific fusion genes, like MLL-AF4 or BCR-ABL, represent heterogeneous disease entities.

Purpose of the Study:

  • To highlight the need for refined risk stratification in pediatric ALL.
  • To emphasize the importance of incorporating dynamic treatment response and minimal residual disease (MRD) assessment.
  • To explore the role of genetic polymorphisms in tailoring therapy and managing toxicity.

Main Methods:

  • Analysis of prognostic significance of genetic abnormalities in ALL.

Related Experiment Videos

  • Evaluation of early therapeutic response and minimal residual disease (MRD) measurement.
  • Investigation of genetic polymorphisms influencing drug pharmacokinetics and pharmacodynamics.

    • Main Results:

    • Primary genetic markers alone are inadequate for precise risk assignment in ALL.
    • Early treatment response and MRD levels significantly enhance risk assessment accuracy.
    • The prognostic impact of genetic abnormalities, such as TEL-AML1 fusion, varies depending on the chemotherapy protocol.

    Conclusions:

    • Accurate risk stratification in pediatric ALL necessitates a multi-faceted approach beyond initial genetic profiling.
    • Integrating MRD assessment and understanding genetic influences on treatment response are crucial for optimizing therapeutic strategies.
    • Future research into genetic polymorphisms will enable personalized medicine, maximizing efficacy while minimizing toxicity in ALL patients.